History
- G+FLAS
- About Us
- History
About Us
-
2020
- Jun.Receive a commendation by Ministry of SMEs and Startups
- Jun.Signed MOU with Chungbuk National University for the development of next-generation genome editing applicational technology
- Apr.Signed MOU with KangStem Biotech for the development of next-generation cell therapy utilizing genome editing technology
- Apr.Granted a patent on CRISPR PLUS® technology
- Mar.Granted a patent on Cas12a protein
- Mar.Succeeded in expressing COVID-19 recombinant vaccine candidate
- Jan.Received Certification of Intellectual Property Management
-
2019
- Osong Campus 1st Plan construction completedOct.
- Secured 12 billion KRW investment from institutional investorsSept.
- Receive a commendation by the president of Korea Invention Promotion AssociationMay.
- Appointed Kee Jong Hong, PhD. as a R&D DirectorApr.
- Commenced construction of Osong Campus 1st plan (plant research center and greenhouse)Apr.
- Acquired Naturegenic, Inc. in the US as a subsidiaryJan.
-
2018
- Dec.Granted 3 patents on closed R-type plant factory system establishment
- Dec.Selected ‘Didimdol Start-up Business Support Project,’ sponsored by Ministry of SMEs and Startups (MSS) of the South Korean government
- Dec.Selected ‘Science-Belt Outcome Support Project,’ sponsored by Ministry of Science and ICT (MSIT) of the South Korean government
- Nov.Granted a patent on ‘Method for Delivering Ribonucleprotein to Plant Protoplast’
- Nov.Implemented joint experiment on delivery material (MMGR) for protoplast transformation with Bio Pact Inc. in the US
- Nov.Branch Establishment (Within Osong Medical Innovation Foundation the development of new pharmaceuticals)
Branch Name : G+FLAS Osong Genome Editing Technology New Pharmaceuticals Research Center - Oct.Selected ‘Technology Venture Scouter Support Project,’ sponsored by Ministry of SMEs and Startups (MSS) of the South Korean government
- Jul.Secured 14 billion KRW ($12.3 million USD) investment from institutional investors
- Jul.Re-selected as a biotech startup by the Ministry of SMEs and Startups (MSS) of the South Korean government
- Jun.Selected as a substitutional military service designated research institute by the South Korean government
- Jan.Moved to the Nakseongdae R & D Center near the Seoul National University
-
2017
- US Patent Application for CRISPR-PLUS™ Technology filedDec.
- started joint development with a global company for Ebola antibody production in the U.S.A.Nov.
- Started joint development with a global company with proven plant-based protein expression system in GermanyNov.
- Selected as a company to enter the Osong Hi-Tech Composite Medical Complex in Chungbuk and acquisition of campus site (5,000 pyong (~ 4 acres)) by the South Korean governmentSep.
- Secured a funding of 4.2 billion KRW ($3.7 million USD) investment from institutional investors (KDB Bank, Ost Investment, The Wells Investment)Mar.
-
2016
- Aug.Dr. Sunghwa Choe inaugurated as the 2nd CEO
- Jul.Selected as a biotech startup by the Ministry of SMEs and Startups (MSS) by the South Korean government and established a research institute
- Apr.Selected as a TIPS company by the Ministry of SMEs and Startups (MSS) of the South Korean government
- Mar.Secured institutional investment (Daesung Private Equity, MiraKle Lab, ActnerLab)
-
2015
- Naturegenic Inc., a US affiliate corporation, moved to the Purdue Research Park of the Purdue UniversitySep.
- Dr. Sunghwa Choe published a research paper on a plant CRISPR genome editing in Nature BiotechnologyOct.
-
2014
- Oct.Started joint research with Seoul National University's Advanced Institutes of Convergence Technology
- Sep.Dr. Kim was inaugurated as the first CEO
- Sep.Established G+FLAS Life Sciences, Inc. in South Korea
- Sep.Established Naturegenic Inc. in the U.S.A.